GlassScriptPhysician profile
Lianrui Li
NPI 1912283235
$4,021.37
in general payments reported to CMS, 2019-2025
25 companies · $45.86 in 2025
The $45.86 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,946 · 2022: $386 · 2023: $1,407 · 2024: $236 · 2025: $45.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.84 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $752.10 | 2021-2023 | Fasenra, Breztri |
| Glaxosmithkline, LLC. | $554.19 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.77 | 2021-2024 | Ofev, Stiolto Respimat |
| Mylan Specialty L.P. | $330.99 | 2021-2023 | Yupelri, Yupelri |
| Regeneron Healthcare Solutions, INC. | $324.07 | 2021-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $304.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.99 | 2021-2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $237.95 | 2023-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $151.56 | 2021-2023 | |
| Harmony Biosciences LLC | $142.02 | 2021-2024 | Wakix |
| Grifols USA, LLC | $100.34 | 2021-2023 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $79.60 | 2021 | |
| Philips North America LLC | $54.52 | 2021-2024 | (Ak6) Vest Therapy |
| Electromed, INC. | $52.93 | 2021-2023 | Smartvest |
| Genentech USA, INC. | $45.05 | 2023 | Xolair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.52 | 2023 | |
| United Therapeutics Corporation | $34.02 | 2023 | Tyvaso |
| Sunovion Pharmaceuticals INC. | $32.07 | 2021 | |
| Baxter Healthcare | $27.81 | 2023 | Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $24.77 | 2023 | Tezspire |
| Resmed Corp | $18.07 | 2024 | |
| Inspire Medical Systems, INC. | $15.76 | 2023 | Inspire |
| Gilead Sciences, INC. | $14.10 | 2021 | |
| Insmed, INC. | $13.72 | 2023 | Arikayce |
| Phadia US INC. | $12.87 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lianrui Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.